Shares of biofuel and specialty enzyme firm Verenium (NASDAQ: [[ticker:VRNM]]) rose slightly this morning on the news that the Cambridge, MA-based firm has inked a deal with St. Louis’s Bunge Oils. Under the agreement, Bunge will fund Verenium’s development of enzymes to improve the production of edible oils, and will become the Cambridge firm’s process implementation partner for Purifine, its first commercial product for seed oil refining.
Author: Rebecca Zacks
Rebecca is Xconomy's co-founder. She was previously the managing editor of Physician's First Watch, a daily e-newsletter from the publishers of New England Journal of Medicine. Before helping launch First Watch, she spent a decade covering innovation for Technology Review, Scientific American, and Discover Magazine's TV show. In 2005-2006 she was a Knight Science Journalism Fellow at MIT. Rebecca holds a bachelor's degree in biology from Brown University and a master's in science journalism from Boston University.
View all posts by Rebecca Zacks
